Biotech Values

[dewophile]

On the surface these data look strong and superior to enta. I too would be curious about lipids as that could be an important differentiator clinically. It’s also curious that the lower dose arm didn’t meet statistical significance on ALT despite very good lowering liver fat. Pruritis a bit more modest but would be nice to know discontinuation rate. I assume they will present details at upcoming meeting.
Perhaps enta should bag 305 unless they think can be differentiated In some way (lipids?). OTOH these data show pruritis is probably independent to some degree of FXR activation In liver and intestine so the enta follow on stands good chance to have improved tolerance and or efficacy.
I think I’ll wait for the smoke to clear and might buy some enta if it drops much farther. Not a lot of catalysts u til back half of the year but it’s certainly looking very cheap if mavyret sales remain steady